Semax and Selank — the deeper history of Russian neuropeptide pharmacology

The intellectual lineage matters for understanding what these compounds actually are.

Semax emerged from the ACTH story. Adrenocorticotropic hormone — ACTH — is a 39-amino-acid peptide secreted by the pituitary gland, best known for stimulating cortisol release from the adrenal cortex. But by the 1970s, researchers had observed that a short fragment of ACTH — specifically the sequence from position 4 to position 10 — produced effects on behavior and cognition in animal models that had nothing to do with adrenal stimulation. ACTH(4-10) appeared to improve memory consolidation, enhance attention, and support recovery from various forms of brain injury, effects that could not be explained by cortisol because the fragment had no adrenotropic activity. The Dutch pharmacologist David de Wied had pioneered much of this research in the 1960s and 1970s, and the Soviet scientific community was paying attention. The Moscow group picked up the thread and asked a chemical question: could the ACTH(4-10) fragment be modified to make it more stable, more bioavailable, and more potent while preserving its cognitive effects?

The synthesis they arrived at added a C-terminal proline-glycine amide modification to the ACTH(4-10) sequence — a structural change that significantly reduced the rate at which peptidases in the body would break the molecule down. The result was a compound with substantially greater metabolic stability than the natural fragment, capable of sustained biological activity after administration. This was the compound registered in Russia under the name Semax, and N.F. Myasoedov, who led much of the synthetic chemistry effort, became one of its primary scientific advocates. It was registered by the Russian Ministry of Health in 1994, initially for the treatment of cerebrovascular insufficiency and cognitive deficits associated with stroke and traumatic brain injury.

The path into clinical use was shaped by Soviet and then Russian medical priorities. Stroke recovery was a major public health problem in the Soviet Union, and the medical establishment was receptive to compounds that appeared to support neurological rehabilitation. The cerebrovascular indication made Semax a mainstream rather than fringe treatment within Russian neurology. It entered pediatric use for developmental disorders. It was used in rehabilitation medicine. The Institute of Molecular Genetics collaborated with clinical institutions to generate the trial data that supported these uses, conducting what amounted to Phase II and Phase III equivalent trials — though by methodologies that differed in some respects from contemporary Western RCT standards, particularly in terms of blinding and sample size.

The mechanistic picture for Semax that assembled through this research period centered on the neurotrophic axis. The most consistent finding across multiple experimental systems was that Semax significantly upregulates BDNF — brain-derived neurotrophic factor — in specific brain regions, particularly the frontal cortex and hippocampus. BDNF is essential for neuronal survival, synaptic plasticity, and the formation of new neural connections; it is one of the molecules most directly implicated in learning, memory consolidation, and recovery from brain injury. The hypothesis that Semax's cognitive effects are mediated substantially through BDNF upregulation is the most mechanistically coherent account of how a short stable peptide could produce the effects the Russian clinical literature describes. Semax also appears to modulate the dopaminergic and serotonergic systems through receptor-level effects rather than direct reuptake inhibition — a distinction that likely explains the qualitative difference between Semax's reported cognitive effects and those of conventional stimulants.

Selank has a different origin but a related logic. The starting point here was tuftsin, a tetrapeptide fragment of immunoglobulin G that plays a role in immune regulation and, less obviously, in anxiety and stress responses. Tuftsin had been identified by Israeli researcher Victor Najjar in the late 1960s and named after Tufts University. The Moscow group's interest in tuftsin was in its central nervous system effects — specifically its apparent anxiolytic properties in animal models, which appeared to be mediated through the neuropeptide Y system and the GABAergic system rather than through direct benzodiazepine-receptor activity. Neuropeptide Y is one of the most abundant neuropeptides in the brain and a key regulator of stress responses, anxiety, and emotional resilience; it is characteristically depleted in chronic stress conditions.

The synthesis challenge was similar to the one the researchers had faced with ACTH(4-10): tuftsin itself was rapidly degraded by peptidases and had poor bioavailability. The Moscow team extended the tuftsin sequence with additional amino acids — adding a sequence that both improved metabolic stability and appeared to enhance the CNS activity of the molecule — and arrived at a seven-amino-acid compound they called Selank. This compound was registered in Russia in 2009 for the treatment of generalized anxiety disorder and as an anxiolytic with a profile distinct from benzodiazepines. The clinical registration required demonstrating efficacy in controlled trials, which the Russian group conducted with sample sizes in the hundreds, finding significant reductions in anxiety measures by standardized rating scales and, crucially, without the sedation, dependence risk, or cognitive blunting that characterizes benzodiazepine use.

The clinical trajectory of both compounds in Russia is worth pausing on, because it represents something the Western market for these peptides often obscures: Semax and Selank are not gray-market research chemicals in their country of origin. They are registered pharmaceutical products, prescribed by Russian physicians, dispensed through pharmacies, and used in standard clinical practice across multiple indications. Semax has been studied in pediatric neurology for children with perinatal brain injuries and developmental delays — an indication that represents significant regulatory and clinical trust in its safety profile. Selank is used in psychiatric practice as an anxiolytic that does not produce the tolerance issues that have driven the Western movement away from benzodiazepines. Neither compound is experimental in the Russian context. They have the equivalent of decades of post-marketing surveillance.

The Western story is a different one. Neither Semax nor Selank has been submitted for FDA approval, and there is no current pathway in progress. The research base, however substantial in volume, faces the same barriers that limit recognition of other Russian pharmaceutical traditions: language barriers, methodological differences, the absence of Western academic institutions with firsthand familiarity with the clinical data, and the economics of drug development for compounds that, as synthetic peptides derived from well-characterized sequences, cannot be exclusively patented by a company willing to fund a Western trial program. The result is that in the United States and Western Europe, these compounds are available primarily through gray-market sourcing channels — research peptide suppliers operating in regulatory ambiguity — and, in some cases, through compounding pharmacies where a prescriber relationship exists and where individual formulation of the compound for a specific patient is possible.

The nootropic and biohacking communities discovered Semax and Selank largely through the translation of Russian pharmaceutical literature by a small number of English-language researchers and enthusiasts in the late 2000s and early 2010s. The reception was enthusiastic, and user reports across online forums broadly corroborated the Russian clinical literature's description of the compounds' effects — with Semax described as producing a quality of focused cognitive enhancement distinct from stimulants, and Selank described as reducing anxious mental noise without sedation. The N-Acetyl Semax variant, which adds an acetyl group for additional stability, became particularly popular in the nootropic community. This consumer ecosystem exists entirely outside formal medical channels and cannot be directly evaluated in terms of dose accuracy, compound purity, or appropriate use.

The intranasal route of administration that both compounds typically use in clinical and consumer settings has a logic rooted in the anatomy of drug delivery. The olfactory mucosa provides a pathway along which peptides can reach the brain more efficiently than via systemic injection, and the olfactory-to-CSF pathway is a well-documented route for nose-to-brain drug delivery. The clinical formulations registered in Russia are nasal sprays. The research literature on intranasal pharmacokinetics for Semax and Selank specifically is not exhaustive — this remains an area where the full picture is not established — but intranasal appears to be the preferred and most-studied route.

What the Semax and Selank story teaches, taken as a whole, is something about parallel pharmaceutical traditions and the ways they do and do not communicate. The research behind these compounds was not conducted in secrecy or by marginal scientists. It was conducted at major Russian academic institutions, by researchers who participated in the international literature in their adjacent fields, and it produced clinical-use products that have been administered to many thousands of patients over decades. The therapeutic hypotheses behind them — that BDNF upregulation supports cognitive recovery, that neuropeptide Y modulation can produce anxiolysis without dependence — are not at odds with what Western neuropharmacology understands about the brain. The gap between Russian clinical practice and Western awareness of these compounds is not primarily a gap in the underlying science. It is a gap produced by language, by institutional distance, by regulatory divergence, and by the economics of pharmaceutical development in a world where commercial incentive shapes which science crosses borders.

Whether that gap closes depends partly on whether Western researchers take the question seriously enough to design the independent replication trials that the Khavinson tradition, and the neuropeptide tradition, both lack. That effort has not yet happened at scale. In the meantime, the clinical experience accumulated across decades of Russian practice represents a body of knowledge that exists — documented, substantial, and largely unread in the countries where most of the people now seeking these compounds live.